Shandong Pharmaceutical Glass Co.Ltd (SHA:600529)
China · Delayed Price · Currency is CNY 20.15
-0.21 (-1.03%)
At close: Feb 13, 2026
SHA:600529 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 4,641 | 5,066 | 4,937 | 4,130 | 3,820 | 3,390 |
Other Revenue | 59.56 | 59.56 | 45.68 | 56.82 | 55.53 | 37.2 |
| 4,701 | 5,125 | 4,982 | 4,187 | 3,875 | 3,427 | |
Revenue Growth (YoY) | -8.43% | 2.87% | 18.98% | 8.05% | 13.08% | 14.53% |
Cost of Revenue | 3,238 | 3,559 | 3,618 | 3,090 | 2,789 | 2,358 |
Gross Profit | 1,463 | 1,566 | 1,364 | 1,098 | 1,086 | 1,069 |
Selling, General & Admin | 374.75 | 341.62 | 332.17 | 251.59 | 230.19 | 227.96 |
Research & Development | 174.94 | 151.76 | 137.95 | 138.94 | 135.63 | 133.87 |
Other Operating Expenses | 38.8 | 39.06 | 33.84 | 32.03 | 31.19 | 32.09 |
Operating Expenses | 586.56 | 534.56 | 515.37 | 434.56 | 407.88 | 407.25 |
Operating Income | 876.42 | 1,031 | 848.58 | 662.95 | 678.38 | 661.36 |
Interest Expense | -0.02 | -0.03 | -0.23 | -0.26 | -0.28 | -0.12 |
Interest & Investment Income | 32.98 | 35.77 | 44.11 | 16.74 | 17.47 | 33.03 |
Currency Exchange Gain (Loss) | 17.22 | 17.22 | 13.01 | 31.5 | -9.48 | -19.25 |
Other Non Operating Income (Expenses) | -6.26 | -2.36 | -2.8 | -0.2 | -2.44 | -3.47 |
EBT Excluding Unusual Items | 920.34 | 1,082 | 902.67 | 710.73 | 683.64 | 671.56 |
Gain (Loss) on Sale of Investments | 12.61 | 24.46 | 22.83 | 3.73 | 9.26 | 0.5 |
Gain (Loss) on Sale of Assets | -0.85 | -1.33 | -12.24 | -3.51 | -22.7 | -27.21 |
Asset Writedown | -55.84 | -5.09 | -12.88 | -16.96 | -11.61 | -8.83 |
Other Unusual Items | 10.74 | 10.74 | 10.44 | 14.06 | 30.13 | 17.45 |
Pretax Income | 887 | 1,111 | 910.82 | 708.05 | 688.72 | 653.48 |
Income Tax Expense | 121.98 | 167.81 | 135.02 | 89.76 | 97.63 | 89.04 |
Earnings From Continuing Operations | 765.01 | 942.99 | 775.8 | 618.29 | 591.09 | 564.44 |
Net Income | 765.01 | 942.99 | 775.8 | 618.29 | 591.09 | 564.44 |
Net Income to Common | 765.01 | 942.99 | 775.8 | 618.29 | 591.09 | 564.44 |
Net Income Growth | -13.26% | 21.55% | 25.48% | 4.60% | 4.72% | 23.05% |
Shares Outstanding (Basic) | 664 | 664 | 663 | 600 | 597 | 594 |
Shares Outstanding (Diluted) | 664 | 664 | 663 | 600 | 597 | 594 |
Shares Change (YoY) | 0.15% | 0.15% | 10.46% | 0.54% | 0.49% | -0.26% |
EPS (Basic) | 1.15 | 1.42 | 1.17 | 1.03 | 0.99 | 0.95 |
EPS (Diluted) | 1.15 | 1.42 | 1.17 | 1.03 | 0.99 | 0.95 |
EPS Growth | -13.39% | 21.37% | 13.59% | 4.04% | 4.21% | 23.38% |
Free Cash Flow | 285.96 | 517.27 | 376.45 | -458.27 | -58.82 | 30.81 |
Free Cash Flow Per Share | 0.43 | 0.78 | 0.57 | -0.76 | -0.10 | 0.05 |
Dividend Per Share | 0.600 | 0.620 | 0.400 | 0.300 | 0.300 | 0.300 |
Dividend Growth | -14.29% | 55.00% | 33.33% | - | - | - |
Gross Margin | 31.12% | 30.55% | 27.38% | 26.21% | 28.03% | 31.18% |
Operating Margin | 18.64% | 20.12% | 17.03% | 15.83% | 17.51% | 19.30% |
Profit Margin | 16.27% | 18.40% | 15.57% | 14.77% | 15.25% | 16.47% |
Free Cash Flow Margin | 6.08% | 10.09% | 7.56% | -10.94% | -1.52% | 0.90% |
EBITDA | 1,306 | 1,416 | 1,174 | 958.13 | 919.03 | 879.26 |
EBITDA Margin | 27.78% | 27.63% | 23.56% | 22.88% | 23.71% | 25.66% |
D&A For EBITDA | 429.51 | 384.77 | 325.13 | 295.17 | 240.64 | 217.9 |
EBIT | 876.42 | 1,031 | 848.58 | 662.95 | 678.38 | 661.36 |
EBIT Margin | 18.64% | 20.12% | 17.03% | 15.83% | 17.51% | 19.30% |
Effective Tax Rate | 13.75% | 15.11% | 14.82% | 12.68% | 14.17% | 13.63% |
Revenue as Reported | 4,701 | 5,125 | 4,982 | 4,187 | 3,875 | 3,427 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.